A r t i c l e s
Tumor-specific antigens are in most cases intracellular proteins, inaccessible to classical mAb therapy. These intracellular proteins are, however, degraded, processed and presented by major histocompatibility complex (MHC) class I molecules as peptide-MHC complexes that can be recognized by the TCR of cytotoxic T lymphocytes (CTLs). Immunotherapies involving CTLs have been central to cancer immunotherapy 1, 2 . However, given the intrinsic complexity of cellbased therapies, alternative approaches using molecular agents would be desirable. Although TCR-mimic mAbs [3] [4] [5] against tumor-specific intracellular antigens have been developed, their potency will be limited by very low epitope density on the cell surface, which reduces efficacy. In contrast, BiTE antibodies-heterodimers of IgG singlechain fragment variable regions (scFv) with dual specificities for a mAb-defined tumor-associated antigen and for CD3 T cells [6] [7] [8] [9] [10] [11] -may be a more promising approach because of their greater potency by virtue of their recruiting of cytolytic T cells. BiTE molecules have been shown to redirect both CD4 and CD8 T cells to kill tumor cells independent of the T cells' intrinsic antigen-specific TCR recognition. Therapeutic BiTE mAbs that have been developed to date are directed to well-known, high-density, cell surface proteins that are not tumorspecific. An example is blinatumomab (Blincyto), which is reactive with the pan B-cell antigen CD19; it has approved by the US Food and Drug Administration for the treatment of B-cell neoplasms 8, 9 .
Here we describe the generation and therapeutic efficacy of a tumor-specific BiTE derived from the high-affinity TCR-mimic antibody ESK1, which specifically binds the Wilms' tumor protein (WT1) epitope RMF, in the context of HLA-A*02:01, the most common HLA-A allele in people of European descent [3] [4] [5] . Despite the ultralow density of expression of the peptide-MHC complex, ESK1-BiTE effectively treated BV173 Ph + acute lymphocytic leukemia (ALL), primary ALL, SET-2 acute myeloid leukemia (AML) and JMN mesothelioma in mouse models. Notably, ESK1-BiTE induced a longlasting, autologous T-cell response in vitro to non-WT1 epitopes, including HER2/Neu, in cells from patients with HER2/Neu + ovarian cancer. Our study suggests that ESK1-BiTE induces epitope spreading-the expansion of T cells against various tumor antigens not targeted by the original therapy-which could provide a broader, more effective and long-term response than the original BiTE-mediated short-term therapy against a single antigen originally targeted.
RESULTS

ESK1-BiTE induces activation of T cells that kill WT1 + cancer cells
The full-length ESK1 mAb binds to cancers and cell lines in a WT1-and HLA-A*02:01-restricted manner 3, 4 . The ESK1-BiTE, a scFv construct, had the expected binding specificity (Supplementary Fig. 1 ). We did not observe binding of ESK to any CD34 + cells from a HLA-A*02:01+ healthy donor (Supplementary Fig. 2a ). The activation of T cells by BiTE constructs depends on the proximal contact between T cells and target cells expressing the target antigens. This proximity also avoids possible unwanted inflammatory responses caused by activation through the invariant CD3 signaling complex 10, 12 . Incubation of ESK1-BiTE with target WT1 + SET-2 AML cells caused a dosedependent interferon (IFN)-γ release in human T cells (Fig. 1a) . CD3 Intracellular tumor antigens presented on the cell surface in the context of human leukocyte antigen (HLA) molecules have been targeted by T cell-based therapies, but there has been little progress in developing small-molecule drugs or antibodies directed to these antigens. Here we describe a bispecific T-cell engager (BiTE) antibody derived from a T-cell receptor (TCR)-mimic monoclonal antibody (mAb) ESK1, which binds a peptide derived from the intracellular oncoprotein WT1 presented on HLA-A*02:01. Despite the very low density of the complexes at the cell surface, ESK1-BiTE selectively activated and induced proliferation of cytolytic human T cells that killed cells from multiple leukemias and solid tumors in vitro and in mice. We also discovered that in an autologous in vitro setting, ESK1-BiTE induced a robust secondary CD8 T-cell response specific for tumorassociated antigens other than WT1. Our study provides an approach that targets tumor-specific intracellular antigens without using cell therapy and suggests that epitope spreading could contribute to the therapeutic efficacy of this BiTE.
1 0 8 0 VOLUME 33 NUMBER 10 OCTOBER 2015 nature biotechnology A r t i c l e s T cells incubated with control-BiTE in the presence of SET-2 cells were not stimulated. When T-cell activation was further evaluated by intracellular cytokine staining, only peripheral blood mononuclear cells (PBMCs), incubated with SET-2 cells in the presence of ESK1-BiTE, showed elevated expression of CD107, CD137, IFN-γ and tumor necrosis factor (TNF)-α, which was sustained over at least 3 d (Supplementary Fig. 2b ). In a HLA-A*02:01-WT1 − ALL cell line, BA-45, such T-cell activation was not elicited. Both CD4 and CD8 T cells were similarly activated in all experimental groups, as expected for CD3 engagement. NK T cell-like cells (CD3 + CD56 + ) were activated, but no changes were observed before or after ESK1-BiTE engagement for CD4 + CD25 + Foxp3 + T-regulatory (T reg ) cells monitored on a daily basis over 3 d.
We next assessed the efficacy and potency of ESK1-BiTE-directed T-cell cytotoxicity in 5-h 51 Cr − release assays with multiple target cancer cell types. In a dose-dependent manner, ESK1-BiTE induced fresh T-cell cytotoxicity against WT-1 + SET-2 AML and BV173 Ph + ALL cells, even at a low effector to target cell (E/T) ratio of 5:1, and a low concentration of 30 ng/ml of ESK1-BiTE, but not against WT1+HLA-A*02:01-HL-60 cells (Fig. 1b-f) , or WT1 − HLA-A*02:01+cells (B-JAB and SKLY-16), which was consistent with the binding specificity. When T-cell cytotoxicity was further titrated on SET-2 and BV173 targets at an E/T ratio of 1:1, the ESK1-BiTE-mediated cytotoxicity was observed to concentrations down to 1 ng/ml ( Supplementary  Fig. 2c ). The cytotoxicity increased up to 90% after longer incubation (Fig. 1b) . Cytotoxicity was also observed against primary ALL blasts (Fig. 1c) . However, despite the specificity seen in these models, because the BiTE may have high enough potency to kill cells that express very few cell surface target sites, a full understanding of the possible on-target, off-tumor toxicity may not be known until human trials.
ESK1-BiTE could also redirect the cytotoxicity of T cells that had previously been repeatedly primed with autologous Epstein-Barr virus (EBV)-transduced B cells containing different viral antigens. Using such EBV-specific T cells allowed us to avoid xenogenic graftversus-host disease in the xenograft animal model, as the T cells were specific for EBV antigens not found in mice. ESK1-BiTE lysed WT-1 + HLA A*02:01 + fresh ovarian cancer cells, Ph + ALL BV173 and JMN mesothelioma in the presence of EBV-specific T cells (Fig. 1g-i) , even more effectively than with fresh PBMCs. Effector cells alone or with control BiTEs did not induce any great cytotoxicity, indicating that the target specificity is required for the T-cell activation. Therefore, ESK1-BiTE specifically redirected potent cytotoxicity of both polyclonal resting T cells and previously sensitized T cells specific for an antigen other than WT1, to lyse tumor cells that were WT-1 + HLA A*02:01 + .
We also investigated the ESK1-BiTE-mediated activation and cytotoxicity of T cells in an autologous setting, thus more closely mimicking the human situation in vivo, using PBMCs from a patient with ovarian cancer with her autologous tumor cells. Dosedependent killing was observed in the cultures with ESK1-BiTE, even with as low as 1,000 PBMCs at the start of the assay ( Supplementary  Fig. 3a) . No killing was observed in the control groups. In parallel, T-cell proliferation was measured by 3 H-thymidine incorporation at the end of 8 d of culture (Supplementary Fig. 3b A r t i c l e s types of cells throughout the entire mouse. T cells alone migrated into the lungs immediately after the injection, then became distributed into other organs including liver, spleen and bone marrow at 8-24 h (Supplementary Fig. 5a ). T-cell signal gradually declined over 72 h. T-cell injection to tumor-bearing mice showed a similar distribution pattern and time course as that of T cells alone. However, mice treated with ESK1-BiTE showed a significant (P < 0.02) increase in T-cell signals in lungs and bone marrow from 8-24 h, which lasted up to 72 h. Cells declined in the lungs substantially, but remained in the liver, spleen and bone marrow. Monitoring the leukemia progression at the same time in these mice revealed an inverse correlation between T-cell retention and leukemia burden ( Supplementary Fig. 5b ). Quantification of bioluminescence intensity showed that 4 h after the ESK1-BiTE injection, there was approximately threefold more T-cell accumulation in the liver, spleen and bone marrow compared to the other two control groups ( Supplementary Fig. 5c ). These results provided evidence in vivo that ESK1-BiTE could mediate prolonged retention of T cells at the leukemia sites, and effectively redirect T cells to the tumor cells expressing WT1-RMF and HLA-A*02:01. However, although the numbers of T cells at the target sites are increased, these data do not address whether the number or the activation state of these cells was critical for the effects observed. We also tested the therapeutic efficacy in vivo of ESK1-BiTE in NSG mice xenografted intravenously with primary ALL cells. T cells were injected intravenously into mice followed by BiTE injection. All mice in the control groups showed increasing tumor growth and massive tumor burdens in the bone marrows and other organs. Dramatic BiTE-dependent tumor inhibition was observed, which was especially prominent in the bone marrow of mice, persisting more than 3 weeks, 9 d after treatment was stopped (Fig. 3a) . The average of photon intensity from five mice showed an approximately 10-to 20-fold tumor reduction in the with or without the ESK1-BiTE to autologous AML blasts from a patient with AML ( Supplementary Fig. 3c-f ).
Treatment of human leukemias expressing WT1/HLA-A*02:01 in NSG mice The anti-leukemic activity of ESK1-BiTE in vivo first was tested using an aggressive AML line, SET-2, which migrates to bone marrow rapidly upon engraftment. Dosing and schedule were guided by pharmacokinetics studies that showed a short, 5 h, beta plasma halflife of the BiTE (Supplementary Fig. 4 ). Luminescence imaging of a luciferase-tagged tumor was used in all therapy experiments to allow precise quantification of the cancer cells throughout the entire mouse, without euthanizing them, thereby also showing the kinetics of the response, and possible regional differences. Such analyses avoid the sampling biases of tumor biopsies when animals are euthanized.
Massive infiltration of leukemia was seen in the bone marrow of NSG (nonobese diabetic (NOD) severe combined immunodeficient (SCID) gamma) mice that received SET-2 cells or SET-2 with allogeneic EBV-specific T cells, or SET-2 with control BiTE (Fig. 2) . However, no detectable leukemia was seen in the group treated with EBV-specific T cells and ESK1-BiTE for up to 14 d and only a minimum leukemia burden was observed up to 25 d, more than a week after treatment was stopped. The control-BiTE group showed slightly delayed leukemia growth on day 14, possibly caused by activation of EBV-specific T cells by the anti-CD3 arm of the control-BiTE. Whereas all the mice in the ESK1-BiTE + T-cell-treated group were still alive after a month, there was little survival in the control groups. In addition, the mice in the ESK1-BiTE-treated group showed no sign of central nervous system (CNS) paralysis caused by leukemia infiltration into vertebral bone marrow for up to 40 d, whereas nearly all animals in the control group developed this leukemic sequela.
ESK1-BiTE mediates T-cell retention at cancer cell sites
Although it is known that BiTE mAbs effectively engage T cells to kill targets in vitro, no studies have reported this mechanism in vivo. We investigated whether the therapeutic efficacy of ESK1-BiTE was the result of its ability to attract T cells and retain them at the sites of leukemia in live animals. Ten million EBV-specific T cells transduced with Renilla luciferase were injected into NSG mice 3 d after firefly luciferase-positive SET-2 AML cells were engrafted. ESK1-BiTE was injected 4 h later. T-cell migration was monitored by bioluminescence imaging. Differential luminescence imaging of luciferase-tagged tumor and T cells simultaneously was used to allow determination of the time course of quantitative localization of both npg A r t i c l e s ESK1-BiTE-treated group when compared to control groups (Supplementary Fig. 6a ). Almost no sign of graft-versus-host disease was observed clinically for up to 49 d after inoculation with tumor cells. These results demonstrated that ESK1-BiTE could efficiently engage and redirect potent T-cell cytotoxicity to kill primary leukemia cells.
Therapy of mesothelioma in NSG mice
We next investigated if ESK1-BiTE is effective in treating an aggressive solid tumor using the JMN peritoneal-cavity mesothelioma. Bioluminescence imaging showed no visible tumor in the mice treated with ESK1-BiTE until more than 2 weeks after treatment, whereas mice in three controls groups showed tumor progression by day 4 (Fig. 3b) . The tumor suppression by ESK1-BiTE persisted until day 23, 18 d after the treatment was stopped, with only a minimum tumor burden seen in the mice. Averaging the bioluminescence intensity of five mice per group showed more than a 20-fold tumor suppression on day 23 ( Supplementary Fig. 6b ) when compared to control groups including tumor cells alone, tumor cells with T cells or tumor cells, T cells and control bite. In addition, therapeutic efficacy was also obtained in disseminated xenograft of Ph + ALL BV173 cells (Supplementary Fig. 6c ).
ESK1-BiTE induced a secondary T-cell response to a HER2/ Neu epitope
The mechanism of action for BiTE mAbs has been attributed exclusively to their capacity to bridge the cancer cell targets and T cells to form a cytolytic synapse. We asked whether such a proximal contact could also directly activate pre-existing T cells in the polyclonal population that were specific for other tumor antigens expressed by the autologous tumor cells. That is, could the BiTE exert an epitope spreading effect? We tested this hypothesis in vitro using T-cells from a HLA-A*02:01 + patient with ovarian cancer. The patient's PBMCs were co-cultured with her autologous tumor cells in the presence of low-dose ESK1-BiTE. A week later, cells were washed and tested for epitope-specific, HLA-A*02:01-restricted T-cell responses by IFN-γ ELISPOT assay. Control groups, including the T cells alone with tumor or with control BiTE and tumor did not show any specific IFN-γ release. The patient's tumor cells express both WT1-RMF and HER2/Neu on their cell surface (Supplementary Fig. 7a-c) . Notably, a strong secondary T-cell response was induced against the HER2/Neu-369 epitope 13 presented by HLA A*02:01 in T2 cells and against the autologous tumor cells alone, as well as against SET-2 AML cells, long after ESK1-BiTE-mediated interactions had ceased (Fig. 4a,b) 18 that are also presented by HLA-A*02:01, or to A*02:01 − HL60 cells. The T-cell response against SET-2 showed recognition of other yet-to-be defined epitopes that are neither WT1 nor HER2/Neu. These results indicate that ESK1-BiTE can induce secondary T-cell responses to multiple tumor antigens, thereby providing a postulated epitope spreading effect.
In principle, a secondary T-cell response should require antigen-presenting cells (APCs) among the PBMCs that could take up and present the intracellular antigens released after tumor cell death. Alternatively, tumor cells could directly activate pre-existing antigen-specific T cells through proximate contact between T cells and tumor. To clarify the mechanism, we asked whether the epitope spreading effect could be elicited with purified T cells, or NK cell-depleted and macrophage-depleted PBMCs (T plus B cells). T cells alone when cultured with autologous ovarian carcinoma cells and the ESK1-BiTE also elicited a T-cell response to HER2/ Neu, autologous tumor cells and SET-2 cells, of a similar magnitude as that produced by T plus B cells (Fig. 4c) or whole PBMCs (Fig. 4d) . To exclude the possibility that activated T cells themselves present these self-cancer antigens, purified T cells were co-cultured with autologous tumor cell lysates, generated by repetitive freeze/ thaw, in the presence or absence of ESK1-BiTE. No T-cell response was seen against the HER2/Neu epitope or tumor cells in this setting (Fig. 4d) . These results suggest that BiTE-mediated interactions between T cells and tumor cells expressing the peptide-HLA We also examined if tumor cell antigen presentation depends on co-stimulatory molecules. Whereas CD14 + monocytes from a healthy donor showed strong CD86 expression, ovarian cancer cells had little expression of the CD86. The results indicated that a key co-stimulatory molecule CD86 is unlikely to be involved in the tumor cell antigen presentation (Supplementary Fig. 8) . No CD86 or ICOSL expression was detected in resting PBMCs or in the tumor cells. Lack of co-stimulatory molecules is one of the reasons that tumor cells are poor APCs; however, certain cytokines may provide co-stimulatory signals to fulfill the requirements for tumor-specific T-cell activation. ESK1-BiTE induced IFN-γ and TNF-α secretion by both PBMCs and T cells (Fig. 4e,f) .
To test if ESK1-BiTE has any long-term effect on the T-cell population, we expanded T cells in vitro in low-dose IL-15 and IL-2, after the first activation by ESK1-BiTE. Whereas T cells in the control groups did not survive more than 1 week in culture, T cells activated by ESK1-BiTE continued to grow for 2 months, without further activation. Phenotype analysis revealed that 7 weeks after activation by ESK1-BiTE and tumor, CD8 + T cells increased to 89% of the population and CD4 + T cells decreased to 6% (Fig. 5a,c) . Among the CD8 + CCR7 − cells, CD45RA − CD45RO + cells increased, indicative of an effector memory phenotype. No TCR gamma delta or invariant NK T cells were detected. However, T cells co-expressing NK marker CD56 increased from 1% to 69%, after the activation, further support of the effector memory formation, as this population indicates a highly specialized effector memory phenotype 19 (Fig. 5b) . Even at this late time point, these T cells still retained their original specificity to autologous tumor and SET-2 AML cells (Fig. 5d) . A reversal of the percentage of CD4 versus CD8 T cells was already evident 3 weeks after ESK1-BiTE activation. Only CD8 T cells acquired the CD56 marker, which was consistent with its cytotoxicity against autologous tumor and SET-2 AML cells (Supplementary Fig. 9 ). These results suggest that the secondary T-cells induced by ESK1-BiTE-mediated tumor interactions might be able to elicit long-lasting, secondary, specific CD8 T-cell responses.
To test the generalizability of this observation, we performed the same experiments in three additional HLA-A*02:01 positive patients with ovarian cancer. We detected a similar T-cell response to the HER2/Neu epitope, autologous tumor cells and ovarian cancer cells in the second patient (Fig. 6a) , whose tumor cells were positive for HER2/Neu, HLA-A*02:01 and WT1-RMF/HLA-A*02:01. PBMCs activated by ESK1-BiTE in the presence of autologous tumor also showed cytotoxicity against autologous tumor cells, primary ovarian cancer cells from the first patient (K-ovarian tumor), and SET-2 cells (which are HER2/Neu − ) but not HL-60 (Fig. 6b) . A similar response was detected in the third patient (HLA-A*02:01+, ESK1 + and HER2/Neu + ) as well. In this case, a lower concentration of ESK1-BiTE (0.01 µg/ml) did not restore T-cell response to the RMF epitope, but it did induce a T-cell response to the HER2/Neu epitope (Fig. 6c) . T cells from the same culture also showed cytotoxicity against the target cells, as seen in the two other patients (Fig. 6d) . No T-cell response was detected in a fourth patient whose tumor cells were not WT1-RMF positive. These results confirmed again that ESK1-BiTE-mediated interaction between T cells and tumor cells was required for eliciting both the primary and secondary response.
To test if the ESK1-BiTE-induced T-cell responses to HER2/Neu was a result of priming of naive T cells or reactivation of pre-existing T cells specific for the HER2/Neu epitope, we performed the same experiments with PBMCs from HLA-A*02:01+ cord blood as effectors and the ovarian cancer cells from the first patient. Cord blood T cells are considered to be antigen-naive and also have lower allo-reactivity, which would confound our results. No T-cell response to the HER2/ Neu epitope or other epitopes in the context of HLA-A*02:01 were detected. The results are consistent with a process in which ESK1-BiTE rapidly activates HER2/Neu epitope-specific T cells that are already present in the patients. Therefore, this secondary T-cell response may be biased toward the cancer present in the patient.
DISCUSSION
In this study, we demonstrated the feasibility and potential applications of a BiTE construct derived from a TCR-mimic mAb, targeting an intracellular tumor-specific protein, WT1 (refs. 20-22) . Our data suggest that the BiTE format can be applied to a much larger universe of targets. By use of an autologous system, we also discovered a BiTE mechanism of action-to our knowledge not previously described-in which the BiTE induced long-lived, secondary, specific T-cell responses against other tumor antigens, such as HER2/Neu. Further, the secondary T-cell responses do not appear to require cross-presentation effected by classical APCs, but rather result from the direct and physically close interaction between T cells and tumor cells, fostered by the BiTE.
Therapeutic TCR-mimic mAbs offer the combined features of T-cell and mAb therapies, joining the functionalities of TCRlike recognition of specific, intracellular tumor antigens and the pharmacologically useful mAb therapeutic activities [3] [4] [5] 23 . We have demonstrated in our previous study that it is feasible for a TCR-mimic mAb to specifically bind and kill cells expressing a peptide-MHC complex at ultra-low density on the cell surface [3] [4] [5] . We have now demonstrated that a TCR-mimic BiTE construct is capable of potent therapeutic activity in several mouse models of both hematopoietic and solid tumors, providing the evidence for vastly broadening the development of BiTE mAbs targeting other cancer-specific intracellular tumor antigens. Although it is known from in vitro assays that BiTEs bring T cells in contact with cancer cells 9, 10 , the dual bioluminescence studies here are consistent with such redirecting in vivo.
The mechanisms of BiTE action to date have been attributed to a direct interaction between T cells and the mAb-specified cellular target that induces short-term T-cell activation and cytotoxicity 9, 10, 12 . The upregulation of CD107 and CD137 expression and increased IFN-γ and TNF-α secretion by fresh T cells from normal donors over 24 and 48 h after ESK1-BiTE activation, with no difference in the ratio between CD4 versus CD8 T cells, suggested broad activation of T cells through CD3 signaling. Notably, in patients with ovarian cancer, we discovered not only this short-term activation and cytotoxicity of T cells, but a secondary T-cell response highly specific for other, non-WT1 cancer antigens. We tested several possible alternate targets that might be expressed by ovarian cancer cells, including multiple epitopes from WT1, PRAME and P53, among others, and identified one, the HER2/Neu epitope 369, known to be both expressed on ovarian cancer cells and highly immunogenic. As SET-2 cells do not express HER2/Neu, there is at least one other recognized target, but there may be many more. Other putative targets may also be presented by other class 1 and class 2 molecules and identifying them would be difficult.
We showed that proximate contact between T cells and live target cells could directly reactivate pre-existing T cells from the patients to react with other cancer antigens, without cross-presentation. The fast, robust and long-lasting HER2/Neu epitope-specific T-cell response, the reversal of the CD4 versus CD8 T-cell ratio, and the dramatic increase of CD8 T cells with effector memory phenotype is evidence that ESK1-BiTE induces CD8 epitope-specific memory T-cell responses. The CD8 T cells were activated to proliferate in response to additional HLA-A*02:01-restricted epitopes. In addition, the epitope-spreading response appears to be a result of reactivation and amplification of pre-existing T cells in patients, because naive T cells from HLA-A*02:01 + cord blood did not respond to ESK1-BiTE in the presence of the same ovarian cancer cells that were both WT1 + and HER2/Neu + . ESK1-BiTE did not induce significant T-cell responses against the original target epitope, WT1-RMF, even though the first patient may have had WT1-reactive T cells in her circulation as a consequence of prior adaptive cell therapy. These findings are consistent with our hypothesis that the BiTE is bringing the T cell's TCRs close to the tumor cell to recognize new peptide-MHC epitopes directly on the tumor. We speculate that one explanation for the lack of WT1 reactivity is that the binding of the ESK1-BiTE to its cognate peptide-MHC during this T-cell stimulation phase may be blocking any recognition of the RMF/HLA-A*02:01 complex from a cognate TCR in the population of T cells.
Although the effects seen here with the ESK1-BiTE have not yet been confirmed in vivo, owing to the inability to generate a non-human model that could accomplish this, nor seen yet with other BiTEs, epitope spreading induced by antigen-specific T-cell vaccines or T-cell infusion is a well-documented phenomenon. In the responding patients or regressing tumors, a considerable expansion of pre-existing and new T cells against various tumor antigens have been detected. It is postulated that vaccinespecific T cells kill the tumor cells and APCs uptake and process the apoptotic tumor cells to activate a variety of T cells, thereby broadening the immune response 24, 25 . An epitope-spreading effect of mAb to CD20 has also been reported; the effect appears to be mediated by antibodymediated opsonization of the target cells into APCs [26] [27] [28] , mechanistically not similar to what we describe here.
T cells directed against various tumor antigens have been found in the blood and tumor sites in patients 1, 24, 25 . Similarly, checkpoint blockade therapy promotes T-cell activation, amplifies pre-existing anti-tumor response and eliminates immunosuppression, including of T reg cells 29, 30 . In addition, whole exomic sequencing approaches to identify neo-antigens from cancer patient's tumor cells and adoptive transfer of T cells generated against such antigens have shown promise 31, 32 . ESK1-BiTE-induced secondary T-cell response may have an effect similar to checkpoint blockade therapy in terms of reactivating anergic or tumor-suppressed T cells, but in the case of BiTE, the response may be tumor specific. We speculate that the activated T cells are likely directed to neo-antigens that have not been identified yet and that this mechanism of ESK1-BiTE action could be highly dependent on the tumor and the patient. It is also interesting to speculate that such effects would not be seen with chimeric antigen receptor T cells, because the T cells have had their specificity redirected by the dominant chimeric antigen receptor.
We chose WT1 peptide RMF as our target for these studies as WT1 has been extensively studied as a oncofetal cancer antigen, with limited expression in adult tissues, outside of kidney podocytes and testes 3, 4, 20, 33, 34 . WT1 is found overexpressed in many human cancer cell types, including leukemias, ovarian cancers and mesothelioma, among others, and was ranked by the National Cancer Institute as the top cancer target 21, 33, 34 . The ESK1-BiTE-mediated cytotoxic T-cell clonal expansion for a variety of tumor-associated epitopes, could contribute greatly to its long-term therapeutic efficacy by preventing the escape of WT1 − cancer cell variants or cells with low WT1 antigen density, as well as by promoting long-lived immunity. In addition, the epitope-spreading effect could be used for ex vivo expansion in advance of specific adoptive T-cell therapy.
METHODS
Methods and any associated references are available in the online version of the paper. EBV-specific T-cell expansion and reporter gene transduction. T-cells were enriched from PBMCs by depletion of monocytes by adhesion. Non-adhering cells were stimulated with irradiated autologous EBV-transformed B cells (EBV-BLCLs) generated by transformation with the B95.8 strain of EBV at a 20:1 responder/stimulator (R/S) ratio and cultured in Yssel's medium, containing 5% HS(YH5; Gemini). Beginning on day 7, interleukin (IL)-2 at 10 to 30 units/ml was added to the T-cell cultures every 2-3 d (Collaborative Biomedical Products, Bedford, MA), and were restimulated weekly with the same EBV-BLCLs at a 4:1 R/S ratio.
EBV-specific T lymphocytes were transduced with retroviral vector tdrrsRLuc, expanded and enriched by sorting for phycoerythrin as previously described 37 . Transduced EBV-specific T lymphocytes were cultured in G-rex flask (Wilson Wolf Manufacturing Corporation). For T-cell tracing study in vivo, ten million cells were in injected into mice and 4 h later, Renilla luciferase substrate ViviRen was given intravenously.
Pharmacokinetic and biodistribution studies. All animal studies were conducted under an IACUC approved protocol. ESK1-BiTE or control BiTE were labeled with 125 I (PerkinElmer) using the chloramine-T method. 100 µg of antibody was reacted with 1 mCi 125 I and 20 µg chloramine-T, quenched with 200 µg Na metabisulfite, then separated from free 125 I using a 10DG column equilibrated with 2% bovine serum albumin in PBS. Specific activity of the product was about 6 mCi/mg. Radiolabeled BiTE (2 µg) was diluted with unlabeled BiTE to 20 µg per dose, and injected into mice retro-orbitally. Blood was collected at various time points, weighed and measured on a gamma counter. At 24 h, organs were harvested, weighed and measured for activity on a gamma counter.
Therapeutic trials of the ESK1-BiTE in human tumor xenograft NSG models.
Human EBV-specific T cells were used for all xenograft models, as their antigenic specificity had been heavily skewed toward EBV antigens, wherein they should not induce graft-versus-host disease. For the SET-2 AML model, one million cells were intravenously injected into mice and the tumor engraftment was confirmed on day 3 by bioluminescence imaging and mice were randomized into treatment groups. On day 4, ten million EBV-specific T cells were injected intravenously and 6 h later, 20 µg ESK1-BiTE or its control BiTE was injected intravenously. Over the treatment course, T cells were given twice a week and BiTEs were given every day for 6 d. In the primary ALL model, five million ALL cells were injected intravenously into NSG mice. On day 6, tumor engraftment was confirmed by firefly luciferase imaging in all mice that were to be treated; mice were then randomly divided into different treatment groups. Thirty million EBV-specific T cells were injected intravenously into mice followed by injection intravenously of 20 µg ESK1-BiTE or its control BiTE. BiTE injection was given daily and T cells were given twice a week for total 2 weeks. For the mesothelioma JMN model, three hundred thousand tumor cells were mixed with six hundred thousand EBV-specific T cells and injected intraperitoneally (ip) and 1 h later, 20 µg ESK1-BiTE or control BiTE was intravenously injected into mice. The BiTEs were given every day for total 5 d. Tumor growth was monitored by firefly luciferase imaging at least twice a week, for all the animal models. 
